Work

Circulating tumor DNA (ctDNA) as an early marker to monitor clinical benefit of regorafenib and TAS-102 in patients with metastatic colorectal cancer (mCRC).

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.3533

Authors: Allan Andresson Lima Pereira, Michael Lam, Preeti Kanikarla Marie, Kanwal Pratap Singh Raghav, Van Karlyle Morris, Hiromi Brown, Justin Windham, Dzifa Yawa Duose, Michael J. Overman, Eduardo Vilar Sanchez, Ignacio Ivan Wistuba, Peter Kipp, Filip Janku, Sudhir Sinha, Scott Kopetz

Institutions: The University of Texas MD Anderson Cancer Center, InnoGenomics (United States), Champions Oncology (United States)

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2890289324

Cites:

Cited by: 4

Related to: 10